BioCentury
ARTICLE | Clinical News

RFVIIIFc: Completed Phase II/III enrollment

June 18, 2012 7:00 AM UTC

Biogen Idec said at its analyst day that it completed enrollment in the open-label, international, pivotal Phase II/III A-LONG trial evaluating a low- and high-dose prophylaxis regimen of IV rFVIIIFc,...